Source link : https://www.newshealth.biz/health-news/should-rsv-vaccination-expand-to-younger-high-risk-groups/
Although the FDA has expanded approvals for two respiratory syncytial virus (RSV) vaccines to include high-risk young and middle-age adults, CDC advisors have not yet moved to recommend the vaccine in these groups. In June, the FDA expanded the approval of GSK’s RSV vaccine (Arexvy) for use in adults ages 50 to 59 at risk […]
Author : News Health
Publish date : 2024-12-01 15:00:00
Copyright for syndicated content belongs to the linked Source.
inHealth